ArticleFrontiers in immunology2026
A high-risk sepsis subtype identified by regulated cell death signatures and MAD2L2 validation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulated cell death (RCD) is closely involved in immune dysregulation and organ injury during sepsis, yet the coordinated transcriptional features of multiple RCD modalities and their relevance to sepsis heterogeneity remain insufficiently characterized. Using the whole-blood transcriptomic cohort GSE65682, we performed consensus clustering of RCD-associated genes and identified four molecular subtypes among 479 patients with sepsis. Cluster 3 showed the poorest 28-day survival (log-rank p = 0.034) and was characterized by a distinct mixed immune transcriptional profile. A sensitivity analysis restricted to apoptosis-, ferroptosis-, necroptosis-, and pyroptosis-associated genes reproduced the primary four-cluster structure and retained the high-risk features of Cluster 3. Integrated differential-expression analysis, weighted gene co-expression network analysis, and complementary machine-learning approaches identified a six-gene signature comprising SMC4, SLC5A6, POLR3GL, MAD2L2, EXOC7, and COG1. The resulting RCD.score closely captured the transcriptional phenotype of Cluster 3. In the external GSE54514 cohort, patients with higher RCD.score values had higher APACHE II scores, and exploratory joint stratification identified a subgroup with both high APACHE II and high RCD.score that had the highest observed mortality. Single-cell analysis localized much of the RCD.score-associated signal to monocyte and dendritic-cell populations. Sample-level analyses showed the clearest sepsis-associated increase in monocytes, with MAD2L2 making the largest positive contribution among the six signature genes. In THP-1 cells, LPS stimulation increased MAD2L2, TNF-α, and IL-1β protein expression, whereas MAD2L2 knockdown reduced these inflammatory proteins and decreased GSDMD-N abundance and caspase-1 processing under both LPS and LPS + ATP conditions. These findings define an RCD-associated high-risk sepsis subtype, provide a cell-type-resolved view of its molecular features, and identify MAD2L2 as a candidate involved in monocyte inflammatory and pyroptosis-associated responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.